ba/f3 cells

5-Acetyl-3-chloro-10,11-dihydro-5H-dibenz[b,f]azepine is a useful organic compound for research related to life sciences. The catalog number is T67591 and the CAS number is 25961-11-9.

3-O-Methyltagitinin F is a useful organic compound for research related to life sciences and the catalog number is T126402.

Ir[p-F(t-Bu)-ppy]3 is a useful organic compound for research related to life sciences and the catalog number is T64556.

H-D-Phe(3-F)-OH, with catalog number T67306 and CAS number 110117-84-5, is a valuable organic compound for research in life sciences.

3'-F-3'-dG(iBu)-2'-phosphoramidite is a Nucleoside Phosphoramidite.

3'-F-3'-dA(Bz)-2'-phosphoramidite is a fluoro-modified nucleoside derivative used as a nucleoside phosphoramidite.

Fmoc-Tyr(3-F, tBu)-OH is a cyclic peptide compound possessing high membrane permeability and exhibiting specific binding affinity towards a target molecule.

Boc-Phe(3-F)-OH is an amino acid derivative and has a wide range of applications in life science related research.

Ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate is a useful organic compound for research related to life sciences. The catalog number is T66942 and the CAS number is 131666-45-0.

3-Chloro-6,11-dihydro-6-methyl-5,5,11-trioxodibenzo[c,f][1,2]thiazepine is a useful organic compound for research related to life sciences. The catalog number is T65901 and the CAS number is 26638-53-9.

Fmoc-D-Phe(3-F)-OH is an organic compound valuable for life sciences research (Catalog No: T65834, CAS No: 198545-72-1).

Boc-D-Phe(3-F)-OH is a useful organic compound for research related to life sciences. The catalog number is T65692 and the CAS number is 114873-11-9.

Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib mesylate has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

(S,R,S)-AHPC TFA (VHL ligand 1 TFA) (VH032-NH2 TFA) is a VH032-based ligand designed for von Hippel-Lindau (VHL) protein recruitment. This compound can be linked to protein ligands (e.g., BCR-ABL1) using a linker to create PROTACs (e.g., GMB-475), which effectively induce the degradation of BCR-ABL1, demonstrated by an IC50 of 1.11 μM in Ba/F3 cells.

ALK ROS1 inhibitor 2e HCL possesses anti-apoptotic, anti-proliferative and anti-tumour activities.

JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for Ba F3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0 G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1].

WF-47-JS03 is a selective and potent inhibitor of RET kinase that crosses the blood-brain barrier and is more than 500-fold more selective for the kinase insertion domain receptor (KDR).WF-47-JS03 acts on Ba/F3 cells transfected with KIF5B-RET (IC50: 1.7 nM) and LC-2/ad lung cancer cells transfected with CCDC6-RET (IC50: 5.3 nM). cells (IC50: 5.3 nM).

Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type. It demonstrates notable antiproliferative effects on Ba/F3 cells expressing CD74-TRKA G667C and ETV6-TRKC G696C, with half-maximal inhibitory concentrations (IC50s) of 6 nM and 1.7 nM, respectively [1].

BCR-ABL-IN-4 is a BCR-ABL inhibitor exhibiting anticancer activity with an inhibitory effect on cancer cell growth, specifically on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba F3 cells (IC50: 16 nM).

HG6-64-1 is a potent and selective inhibitor of B-Raf, with an IC50 of 0.09 μM on B-raf V600E-transformed Ba F3 cells.

Aspochalasin D, a co-metabolite originally isolated from A. microcysticus along with aspochalasins A, B, and C, has antibacterial activity against Gram-positive and Gram-negative bacteria at a concentration of 1 mg ml. Aspochalasin D is more cytotoxic via apoptosis to Ba F3-V12 cells in an IL-3-free medium [IC50 = 0.49 μg ml] than in an IL-3-containing medium [IC50 = 1.9 μg ml].

TRK-IN-23 (compound 24b) is a potent, orally active TRK inhibitor with IC50s of 0.5 nM for TRKA, 9 nM for TRKC, 14 nM for TRKA G595R, 4.4 nM for TRKA F589L, and 4.8 nM for TRKA G667C. It induces apoptosis in Ba F3-TRKAG595R and Ba F3-TRKAG667C cells [1].

AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.

ALK-IN-27 (compound 1) is a potent ALK inhibitor with an IC50 of 2.7 nM in Ba F3 CLIP1-LTK cells, demonstrating significant antitumor activity [1].

EGFR-IN-97 (compound 6q), an EGFR inhibitor, demonstrates effectiveness in inhibiting Ba F3-EGFR L858R T790M C797S and Ba F3-EGFR Del19 T790M C797S cells, exhibiting IC 50 values of 0.42 μM and 0.41 μM, respectively. Additionally, at a concentration of 0.8 μM, EGFR-IN-97 is capable of inducing apoptosis in NCI-H1975-EGFR L858R T790M C797S cells [1].

FLT3-IN-22 (compound 22f) is a potent FLT3 inhibitor with IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3 D835Y mutant. It demonstrates significant antiproliferative effects against MV4-11 cells and Ba F3 cell lines expressing mutant FLT kinase variants, including FLT-D835Y and FLT3-F691L [1].

TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L, with corresponding IC50 values of 5.21, 4.51, 6.77, 1.42, and 6.13 nM. It demonstrates antitumor activity in BaF3-CD74-NTRK1 G595R and BaF3-CD74-NTRK1 G667C xenograft models and inhibits the proliferation of Ba F3 cells expressing single mutants SF, GK, and xDFG, with an IC50 range of 1.43-47.56 nM [1].

AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Biochemical assays with purified glutathione S transferase (GST)-Abl kinase domain confirmed that AP23464 directly inhibits Abl activity. Importantly, the low nanomolar cellular and biochemical inhibitory properties of AP23464 extend to frequently observed imatinib mesylate-resistant Bcr-Abl mutants, including nucleotide binding P-loop mutants Q252H, Y253F, E255K, C-terminal loop mutant M351T, and activation loop mutant H396P. AP23464 was ineffective against mutant T315I, an imatinib mesylate contact residue. The potency of AP23464 against imatinib mesylate-refractory Bcr-Abl and its distinct binding mode relative to imatinib mesylate warr......

BCR-ABL-IN-3 is a highly effective, irreversible inhibitor of Bcr-Abl, with an IC50 value of ≤100 nM for Ba F3 Bcr-Abl T3151, displaying significant anti-cancer activity.

(S,R,S)-AHPC (VH032-NH2) is a VH032-based ligand for recruiting the von Hippel-Lindau (VHL) protein, potentially useful for the targeted degradation of the androgen receptor.

cis VH 032, amine dihydrochloride ((S,S,S)-AHPC) is a negative control for the functionalized VHL ligand VH 032, amine .

(S,R,S)-AHPC is a VHL ligand that used in the recruitment of the VHL protein.

(S,R,S)-AHPC hydrochloride (Protein degrader 1 hydrochloride) is a building block in the synthesis of proteolysis-targeting chimera technologies (PROTACs).

(S,S,S)-AHPC hydrochloride ((S,S,S)-VH032-NH2 hydrochloride) is a VHL amino building block and ligand used as a negative control for (S,R,S)-AHPC. It is based on VH032 and is employed in the recruitment of the VHL protein.